OurProteinFactory

Uniform Biological Material Transfer Agreement – MTA

Definitions

1. PROVIDER: Organization providing the ORIGINAL MATERIAL. The name and address of this party will be specified in an implementing letter.
2. PROVIDER SCIENTIST: The name and address of this party will be specified in an implementing letter.
3. RECIPIENT: Organization receiving the ORIGINAL MATERIAL. The name and address of this party will be specified in an implementing letter.
4. RECIPIENT SCIENTIST: The name and address of this party will be specified in an implementing letter.
5. ORIGINAL MATERIAL: The description of the material being transferred will be specified in an implementing letter.
6. MATERIAL: ORIGINAL MATERIAL, and PROGENY. The MATERIAL shall not include: (a) MODIFICATIONS, or (b) other substances created by the RECIPIENT through the use of the MATERIAL which are not MODIFICATIONS, PROGENY, or UNMODIFIED DERIVATIVES.
7. PROGENY: Unmodified descendant from the MATERIAL, such as virus from virus, cell from cell, or organism from organism, DNA/RNA duplicated by DNA/RNA supplied by the PROVIDER, purified or fractionated subsets of the ORIGINAL MATERIAL.
8. UNMODIFIED DERIVATIVES: Substances created by the RECIPIENT which constitute an unmodified functional subunit or product expressed by the ORIGINAL MATERIAL. Some examples include: proteins expressed by DNA/RNA supplied by the PROVIDER, or monoclonal antibodies secreted by a hybridoma cell line.
9. MODIFICATIONS: Substances created by the RECIPIENT which contain/incorporate the MATERIAL, and UNMODIFIED DERIVATIVES.
10. COMMERCIAL PURPOSES: The sale, lease, license, or other transfer of the MATERIAL or MODIFICATIONS to a for-profit organization. COMMERCIAL PURPOSES shall also include uses of the MATERIAL or MODIFICATIONS by any organization, including RECIPIENT, to perform contract research, to screen compound libraries, to produce or manufacture products for general sale, or to conduct research activities that result in any sale, lease, license, or transfer of the MATERIAL or MODIFICATIONS to a for-profit organization. However, industrially sponsored academic research shall not be considered a use of the MATERIAL or MODIFICATIONS for COMMERCIAL PURPOSES per se, unless any of the above conditions of this definition are met.
11. NONPROFIT ORGANIZATION(S): A university or other institution of higher education or an organization any nonprofit scientific or educational organization qualified under a nonprofit organization statute. As used herein, the term also includes government agencies.

Terms and Conditions of this Agreement

1. The PROVIDER retains ownership of the MATERIAL, including any MATERIAL contained or incorporated in MODIFICATIONS.

2. The RECIPIENT retains ownership of: (a) MODIFICATIONS (except that, the PROVIDER retains ownership rights to the MATERIAL included therein), and (b) those substances created through the use of the MATERIAL or MODIFICATIONS, but which are not PROGENY, UNMODIFIED DERIVATIVES or MODIFICATIONS (i.e., do not contain the ORIGINAL MATERIAL, PROGENY, UNMODIFIED DERIVATIVES). If either 2 (a) or 2 (b) results from the collaborative efforts of the PROVIDER and the RECIPIENT, joint ownership may be negotiated.

a) is to be used solely for teaching and academic research purposes;
b) will not be used in human subjects, in clinical trials, or for diagnostic purposes involving human subjects without the written consent of the PROVIDER;
c) is to be used only at the RECIPIENT organization and only in the RECIPIENT SCIENTIST's laboratory under the direction of the RECIPIENT SCIENTIST or others working under his/her direct supervision;
d) will not be transferred to anyone else outside the RECIPIENT organization without the prior written consent of the PROVIDER.

4. The RECIPIENT and the RECIPIENT SCIENTIST agree to refer to the PROVIDER any request for the MATERIAL from anyone other than those persons working under the RECIPIENT SCIENTIST's direct supervision. To the extent supplies are available, the PROVIDER or the PROVIDER SCIENTIST agrees to make the MATERIAL available, under a separate implementing letter to this Agreement or other agreement having terms consistent with the terms of this Agreement, to other scientists (at least those at NONPROFIT ORGANIZATION(S)) who wish to replicate the RECIPIENT SCIENTIST's research; provided that such other scientists reimburse the PROVIDER for any costs relating to the preparation and distribution of the MATERIAL.

a) The PROVIDER and/or the PROVIDER SCIENTIST shall have the right, without restriction, to distribute substances created by the PROVIDER through the use of the ORIGINAL MATERIAL only if those substances are not PROGENY, UNMODIFIED DERIVATIVES, or MODIFICATIONS.
b) Under a separate implementing letter to this Agreement (or an agreement at least as protective of the PROVIDER's rights), the RECIPIENT and/or the RECIPIENT SCIENTIST may distribute substances created by the RECIPIENT through the use of the ORIGINAL MATERIAL only if those substances are not PROGENY, UNMODIFIED DERIVATIVES, or MODIFICATIONS.
c) The PROVIDER and/or the PROVIDER SCIENTIST shall have the right, without restriction, to distribute MODIFICATIONS to NONPROFIT ORGANIZATION(S) for research and teaching purposes only.
d) The PROVIDER and/or the PROVIDER SCIENTIST shall have the right, without restriction, to distribute MATERIAL for COMMERCIAL PURPOSES. It is recognized by the PROVIDER that such COMMERCIAL PURPOSES may NOT require a commercial license from the RECIPIENT and the RECIPIENT has no obligation to grant a commercial license to its ownership interest in the MATERIAL. Nothing in this paragraph, however, shall prevent the PROVIDER from granting commercial licenses under the PROVIDER's intellectual property rights claiming such MATERIAL, or methods of their manufacture or their use.
e) The RECIPIENT and/or the RECIPIENT SCIENTIST shall have the right, without restriction, to distribute MODIFICATIONS for COMMERCIAL PURPOSES. It is recognized by the RECIPIENT that such COMMERCIAL PURPOSES may NOT require a commercial license from the PROVIDER and the PROVIDER has no obligation to grant a commercial license to its ownership interest in the MATERIAL incorporated in the MODIFICATIONS. Nothing in this paragraph, however, shall prevent the RECIPIENT from granting commercial licenses under the RECIPIENT's intellectual property rights claiming such MODIFICATIONS, or methods of their manufacture or their use.

6. The RECIPIENT acknowledges that the MATERIAL is or may be the subject of a patent application. Except as provided in this Agreement, no express or implied licenses or other rights are provided to the RECIPIENT under any patents, patent applications, trade secrets or other proprietary rights of the PROVIDER, including any altered forms of the MATERIAL made by the PROVIDER. In particular, no express or implied licenses or other rights are provided to use the MATERIAL, MODIFICATIONS, or any related patents of the PROVIDER for COMMERCIAL PURPOSES.

7. If the RECIPIENT desires to use or license the MATERIAL for COMMERCIAL PURPOSES, the RECIPIENT agrees, in advance of such use, to negotiate in good faith with the PROVIDER to establish the terms of a commercial license. It is understood by the RECIPIENT that the PROVIDER shall have no obligation to grant such a license to the RECIPIENT, and may grant exclusive or non-exclusive commercial licenses to others, or sell or assign all or part of the rights in the MATERIAL to any third party(ies), subject to any pre-existing rights held by others and obligations to the Federal Government.

8. If the PROVIDER desires to use or license the MODIFICATIONS for COMMERCIAL PURPOSES, the PROVIDER agrees, in advance of such use, to negotiate in good faith with the RECIPIENT to establish the terms of a commercial license. It is understood by the PROVIDER that the RECIPIENT shall have no obligation to grant such a license to the PROVIDER, and may grant exclusive or non-exclusive commercial licenses to others, or sell or assign all or part of the rights in the MODIFICATIONS to any third party(ies), subject to any pre-existing rights held by others and obligations to theGovernment.

9. The PROVIDER is free to file patent application(s) claiming inventions made by the PROVIDER through the use of the MODIFICATIONS but agrees to notify the RECIPIENT upon filing a patent application claiming MATERIAL or method(s) of manufacture or use(s) of the MATERIAL.

10. The RECIPIENT is free to file patent application(s) claiming inventions made by the RECIPIENT through the use of the MATERIAL but agrees to notify the PROVIDER upon filing a patent application claiming MODIFICATIONS or method(s) of manufacture or use(s) of the MATERIAL.

11. Any MATERIAL delivered pursuant to this Agreement is understood to be experimental in nature and may have hazardous properties. The PROVIDER MAKES NO REPRESENTATIONS AND EXTENDS NO WARRANTIES OF ANY KIND, EITHER EXPRESSED OR IMPLIED. THERE ARE NO EXPRESS OR IMPLIED WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, OR THAT THE USE OF THE MATERIAL WILL NOT INFRINGE ANY PATENT, COPYRIGHT, TRADEMARK, OR OTHER PROPRIETARY RIGHTS.

12. Except to the extent prohibited by law, the RECIPIENT assumes all liability for damages which may arise from its use, storage or disposal of the MATERIAL. The PROVIDER will not be liable to the RECIPIENT for any loss, claim or demand made by the RECIPIENT, or made against the RECIPIENT by any other party, due to or arising from the use of the MATERIAL by the RECIPIENT, except to the extent permitted by law when caused by the gross negligence or willful misconduct of the PROVIDER.

13. This agreement shall not be interpreted to prevent or delay publication of research findings resulting from the use of the MATERIAL or the MODIFICATIONS. The PROVIDER SCIENTIST agrees to provide appropriate acknowledgment of the source of the MODIFICATIONS in all publications. The RECIPIENT SCIENTIST agrees to provide appropriate acknowledgment of the source of the MATERIAL in all publications.

14. The PROVIDER agrees to use the MODIFICATIONS in compliance with all applicable statutes and regulations, including Public Health Service and National Institutes of Health regulations and guidelines such as, for example, those relating to research involving the use of animals or recombinant DNA. The RECIPIENT agrees to use the MATERIAL in compliance with all applicable statutes and regulations, including Public Health Service and National Institutes of Health regulations and guidelines such as, for example, those relating to research involving the use of animals or recombinant DNA.

i) if termination should occur under 15(a), the RECIPIENT shall be bound to the PROVIDER by the least restrictive terms applicable to the MATERIAL obtained from the then-available resources; and
ii) if termination should occur under 15(b) or (d) above, the RECIPIENT will discontinue its use of the MATERIAL and will, upon direction of the PROVIDER, return or destroy any remaining MATERIAL. The RECIPIENT, at its discretion, will also either destroy the MODIFICATIONS or remain bound by the terms of this agreement as they apply to MODIFICATIONS; and
iii) In the event the PROVIDER terminates this Agreement under 15( c) other than for breach of this Agreement or for cause such as an imminent health risk or patent infringement, the PROVIDER will defer the effective date of termination for a period of up to one year, upon request from the RECIPIENT, to permit completion of research in progress. Upon the effective date of termination, or if requested, the deferred effective date of termination, RECIPIENT will discontinue its use of the MATERIAL and will, upon direction of the PROVIDER, return or destroy any remaining MATERIAL. The RECIPIENT, at its discretion, will also either destroy the MODIFICATIONS or remain bound by the terms of this agreement as they apply to MODIFICATIONS.

16.Paragraphs 6, 11 and 12 shall survive termination.

17.The MATERIAL is provided at no cost, or with an optional transmittal fee solely to reimburse the PROVIDER for its preparation and distribution costs. If a fee is requested by the PROVIDER, the amount will be indicated in an implementing letter. Main Text Ends Here.

RECIPIENT: Kangma-Healthcode (Shanghai) Biotech Co. Ltd.
RECIPIENT SCIENTIST: Rongrong Zhan
RECIPIENT ADDRESS: Building 15, Lane 118 Furonghua Road, Shanghai 201321, CHINA
RECIPIENT TEL: 021-58086922
RECIPIENT EMAIL: customer@healthcodon.com

协议说明

提示

阅读并同意隐私协议、MTA和使用条款后进行下一步!

coronaViruses

CoronaViruses Sequence Comparison

原创 proteinn 蛋白质工厂昨天

On February 11, 2020, the World Health Organization WHO named the viral respiratory disease in humans originated from Wuhan, China, as coronavirus disease 2019 (abbreviated “COVID-19”). COVID-19 is associated with a new RNA coronavirus (2019-nCoV).

Severe acute respiratory syndrome (SARS) is a viral respiratory illness caused by a coronavirus called SARS-associated coronavirus (SARS-CoV). SARS was first reported in Asia in February 2003. The illness spread to more than two dozen countries in North America, South America, Europe, and Asia before the SARS global outbreak of 2003 was contained.

Middle East Respiratory Syndrome (MERS) is an illness caused by a virus (more specifically, a coronavirus) called Middle East Respiratory Syndrome Coronavirus (MERS-CoV). Most MERS patients developed severe respiratory illness with symptoms of fever, cough and shortness of breath. About 3 or 4 out of every 10 patients reported with MERS have died.

Figure 1.Schematics of 2019-nCoV, SARS-CoV, MERS-CoV genome, ORF and protein.

The following analysis is based on the most up-to-date 2019-nCoV genome sequence Refseq: NC_045512 [1].

Genome

For genome sequence, the 2019-nCoV RNA (29903 bases) shares 80.08% homology to SARS-CoV (29751 bases, Refseq. NC_004718), 58.79% to MERS-CoV (30119 bases, Refseq. NC_019843). The homology between SARS-CoV and MERS-CoV genome sequences is 47.07%.

Table 1.Orthogonal Array of 3 Genomic RNAs Homology.

Homology	2019-nCoV 29903 b	SARS-nCoV 29751 b	MERS-nCoV 30119 b
2019-nCoVRefseq. NC_045512	100%	80.08%	58.79%
SARS-CoV Refseq. NC_004718		100%	47.07%
MERS-CoV Refseq. NC_019843			100%

Picture from [2]

Protein

The 2019-nCoV encodes 15 ORFs, 28 proteins，with 1 more ORF than SARS-nCoV (14 ORFs, 27 proteins) , 4 more ORFs than MERS-nCoV (11 ORFs, 24 proteins).

Table 2. Number of ORF and Protein in the 3 coronaviruses.

Number	ORF	Protein
2019-nCoV	15	28
SARS-nCoV	14	27
MERS-nCoV	11	24

Among the 15 ORFs, two ORFs (orf6, orf7a) are not found in SARS-CoV or MERS-CoV, thus unique to 2019-nCoV. 2019-nCoV lacks one ORF (orf9b) that only exists in SARS-nCoV, and three ORFs (orf4a, orf4b, orf5) that only exist in MERS-nCoV.

Table 3. Proteins encoded in the 3 coronaviruses.

Protein\Residue Number	2019-nCoV	SARS-nCoV	MERS-nCoV
5' UTR	/	/	/
Host translation inhibitor NSP1	180	180	193
Non-structural protein 2	638	638	660
Papain-like proteinase	1945	1922	1887
Non-structural protein 4	500	500	507
3C-like proteinase	306	306	306
Non-structural protein 6	290	290	292
Non-structural protein 7	83	83	83
Non-structural protein 8	198	198	199
Non-structural protein 9	113	113	110
Non-structural protein 10	139	139	140
RNA-directed RNA polymerase	932	932	933
Helicase	601	601	598
Guanine-N7 methyltransferase	527	527	524
Uridylate-specific endoribonuclease	346	346	343
2'-O-methyltransferase	298	210	303
Spike glycoprotein (S)	1273	1255	1353
orf 3a	275	274	103
Envelope protein (E)	75	76	82
Membrane glycoprotein (M)	222	221	219
orf 4a	/	/	109
orf 4b	/	/	246
orf 5	/	/	224
orf 6	61	63	/
orf 7a	121	122	/
orf 8	121	84	112
Nucleocapsid phosphoprotein (N)	419	422	413
orf9b	/	98	/
orf 10	38	/	/
3' UTR	/	/	/

a. The length of each protein is displayed. .

b. “/” means that no protein is encoded.

Table 4. Protein Homology in the 3 coronaviruses.

Protein Name\Identity	2019-n/SARS	2019-n/MERS	SARS/MERS
Host translation inhibitor NSP1	84.4%	25.7%	25.0%
Non-structural protein 2	68.3%	21.4%	21.9%
Papain-like proteinase	76.7%	33.2%	32.9%
Non-structural protein 4	80.0%	39.6%	38.2%
3C-like proteinase	96.8%	50.8%	51.8%
Non-structural protein 6	87.2%	34.8%	34.8%
Non-structural protein 7	98.8%	55.4%	55.4%
Non-structural protein 8	97.5%	52.8%	52.3%
Non-structural protein 9	97.4%	53.6%	53.6%
Non-structural protein 10	97.1%	59.0%	59.0%
RNA-directed RNA polymerase	96.4%	72.6%	72.3%
Helicase	99.8%	71.6%	71.6%
Guanine-N7 methyltransferase	95.1%	63.4%	63.2%
Uridylate-specific endoribonuclease	88.7%	51.8%	50.0%
2'-O-methyltransferase	93.3%	66.1%	65.1%
Spike glycoprotein (S)	77.7%	33.3%	33.7%
orf 3a	72.9%	7.2%	8.3%
orf 3b	7.8%	/	/
Envelope protein (E)	93.2%	36.5%	36.8%
Membrane glycoprotein (M)	91.0%	40.2%	42.0%
orf 7a	86.0%	/	/
orf 7b	83.3%	/	/
orf 8	57.0%	17.1%	16.2%
Nucleocapsid phosphoprotein (N)	91.2%	49.9%	49.6%
orf 9a	73.2%	/	/
orf 14	77.1%	/	/

References.

1. Wuhan seafood market pneumonia virus isolate Wuhan-Hu-1, complete genome. NCBI Reference Sequence: NC_045512.2

https://www.ncbi.nlm.nih.gov/nuccore/1798174254

2. A decade after SARS: strategies for controlling emerging coronaviruses. Graham RL1, Donaldson EF, Baric RS. Nat Rev Microbiol. 2013 Dec;11(12):836-48.

3. Original Analysis by TT Hang, KK Zheng, XQ Ju, M Guo, Kangma-

Healthcode.com

4. Full genome alignment of 2019-nCoV, SARS-CoV, MERS-CoV can be found at

OurProteinFactory.com/2019-nCoV/genomealign